SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001640455-17-000028
Filing Date
2017-05-09
Accepted
2017-05-09 13:49:31
Documents
56
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q jnce0331201710-q.htm 10-Q 1064692
2 EXHIBIT 31.1 jnce03312017exhibit311.htm EX-31.1 10396
3 EXHIBIT 31.2 jnce03312017exhibit312.htm EX-31.2 10393
4 EXHIBIT 32.1 jnce03312017exhibit321.htm EX-32.1 11727
  Complete submission text file 0001640455-17-000028.txt   4873338

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT jnce-20170331.xml EX-101.INS 839707
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20170331.xsd EX-101.SCH 37535
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT jnce-20170331_cal.xml EX-101.CAL 54001
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT jnce-20170331_def.xml EX-101.DEF 259216
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20170331_lab.xml EX-101.LAB 532918
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20170331_pre.xml EX-101.PRE 328585
Mailing Address 1030 MASSACHUSETTS AVE. CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVE. CAMBRIDGE MA 02138 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37998 | Film No.: 17825686
SIC: 2836 Biological Products, (No Diagnostic Substances)